BlasticidinS是一种来自Streptomyces griseochromogenes的核苷类抗生素，通过干扰核糖体中肽键的形成来特异性地抑制原核和真核生物的蛋白质合成。BlasticidinS用于筛选携带有bsr或BSD耐受基因的转染细胞。杀稻瘟菌素具有快速而强效的作用模式，很低的抗生素浓度便能导致细胞迅速死亡。
Cat#60218ES10、60218ES50、60218ES60均以液体形式提供，浓度为10 mg/mL（in HEPES缓冲液，pH 7.5）。
Cat#60218ES80为粉末形式提供，使用时可用无菌水或者缓冲液配制成5-10 mg/mL的储存液。
相关产品推荐：
| 产品名称 | 产品编号 |
| Carbenicillin, Disodium Salt 羧苄青霉素钠 | 60202ES |
| Ampicillin, Sodium Salt 氨苄青霉素钠 | 60203ES |
| Doxycycline hyclate 盐酸强力霉素 | 60204ES |
| Chloramphenicol, USP Grade 氯霉素，USP级 | 60205ES |
| Kanamycin Sulfate 硫酸卡那霉素 | 60206ES |
| Puromycin Dihydrochloride嘌呤霉素盐酸盐 | 60210ES |
| Tetracyclin HCl 四环素盐酸盐（USP） | 60212ES |
| Vancomycin Hydrochloride 盐酸万古霉素 | 60213ES |
| Gentamycin Sulfate Salt 硫酸庆大霉素 | 60214ES |
| Spectinomycin Hydrochloride 盐酸壮观霉素 | 60215ES |
| 盐酸博莱霉素 | 60216ES |
| Phleomycin (20mg/ml in solution) 腐草霉素 | 60217ES |
| Blasticidin S 杀稻瘟菌素S （灭瘟素） | 60218ES |
| Nystatin 制真菌素 | 60219ES |
| G418 Sulfate (Geneticin) 遗传霉素 | 60220ES |
| Hygromycin B 潮霉素B | 60225ES |
| Erythromycin 红霉素 | 60228ES |
| Timentin 特美汀 | 60230ES |
| Aureobasidin A （AbA）金担子素A | 60231ES |
| Polymyxin B Sulfate 多粘菌素B硫酸盐 | 60242ES |
-25~-15℃保存。粉末有效期3年，液体有效期2年，避免反复冻融。
[1] Zhang Y, Wang Q, Han Y, Wang Y, Zhao L, Zhou H, Zhang R, Wang S, Jin X, Piao J. RNA-binding protein HnRNPU regulates proliferation and ferroptosis in colon adenocarcinoma by stabilizing the mRNA of system xc. Exp Mol Med. 2025 Nov;57(11):2686-2698. doi: 10.1038/s12276-025-01569-z. Epub 2025 Nov 28. PMID: 41310105; PMCID: PMC12686487. (IF:12.9)
[2] Xiao J, Xiong Y, Yang LT, et al. POST1/C12ORF49 regulates the SREBP pathway by promoting site-1 protease maturation. Protein Cell. 2021;12(4):279-296. doi:10.1007/s13238-020-00753-3(IF:10.164)
[3] Wei W, Li Y, Wang C, et al. Diterpenoid Vinigrol specifically activates ATF4/DDIT3-mediated PERK arm of unfolded protein response to drive non-apoptotic death of breast cancer cells [published online ahead of print, 2022 Jun 1]. Pharmacol Res. 2022;182:106285. doi:10.1016/j.phrs.2022.106285(IF:7.658)
[4] Qian F, Hu Q, Tian Y, et al. ING4 suppresses hepatocellular carcinoma via a NF-κB/miR-155/FOXO3a signaling axis. Int J Biol Sci. 2019;15(2):369-385. Published 2019 Jan 1. doi:10.7150/ijbs.28422(IF:6.582)
[5] Li Q, Yu D, Yu Z, et al. TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular signal-regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis. Transl Lung Cancer Res. 2021;10(2):936-954. doi:10.21037/tlcr-21-147(IF:6.498)
[6] Li Y, Fu Y, Hu X, et al. The HBx-CTTN interaction promotes cell proliferation and migration of hepatocellular carcinoma via CREB1. Cell Death Dis. 2019;10(6):405. Published 2019 May 28. doi:10.1038/s41419-019-1650-x(IF:5.959)
[7] Li X, Wu A, Han C, et al. Bone marrow-derived mesenchymal stem cells in three-dimensional co-culture attenuate degeneration of nucleus pulposus cells. Aging (Albany NY). 2019;11(20):9167-9187. doi:10.18632/aging.102390(IF:5.515)
[8] Yue C, Jin H, Zhang X, et al. Aucubin prevents steroid-induced osteoblast apoptosis by enhancing autophagy via AMPK activation. J Cell Mol Med. 2021;25(21):10175-10184. doi:10.1111/jcmm.16954(IF:5.310)
[9] Xiong Y, Luo J, et al. Hyperactivation of SREBP induces pannexin-1-dependent lytic cell death. J Lipid Res. 2024 Jul;65(7):100579. doi: 10.1016/j.jlr.2024.100579. Epub 2024 Jun 14. PMID: 38880128; PMCID: PMC11284708. (IF:5)
[10] Wu J, Lv Q, He J, et al. MicroRNA-188 suppresses G1/S transition by targeting multiple cyclin/CDK complexes. Cell Commun Signal. 2014;12:66. Published 2014 Oct 11. doi:10.1186/s12964-014-0066-6(IF:4.672)
[11] Huang H, Zou X, Zhong L, et al. CRISPR/dCas9-mediated activation of multiple endogenous target genes directly converts human foreskin fibroblasts into Leydig-like cells. J Cell Mol Med. 2019;23(9):6072-6084. doi:10.1111/jcmm.14470(IF:4.658)
[12] Huang H, Zhong L, Zhou J, et al. Leydig-like cells derived from reprogrammed human foreskin fibroblasts by CRISPR/dCas9 increase the level of serum testosterone in castrated male rats. J Cell Mol Med. 2020;24(7):3971-3981. doi:10.1111/jcmm.15018(IF:4.486)
